Interferon α augments activation-induced T cell death by upregulation of Fas (CD95/APO-1) and Fas ligand expression

Cytokine

Volumn 11, Issue 10, 1999, Pages 736-743

  Kaser, Arthur ^a   Nagata, Shigekazu ^b   Tilg, Herbert ^a  

^a UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^b OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

AICD; Apoptosis; Fas; FasLIFN

Indexed keywords

2',5' OLIGOADENYLIC ACID; ALPHA INTERFERON; ANTIBODY; FAS ANTIGEN; FAS LIGAND; FLUORESCEIN ISOTHIOCYANATE; LIPOCORTIN 5; MESSENGER RNA; PROPIDIUM IODIDE; RECOMBINANT ALPHA2B INTERFERON;

ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CELL DEATH; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOMODULATION; MONONUCLEAR CELL; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

EID: 0032820721     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1006/cyto.1998.0484     Document Type: Article

References (41)

1. Cohen JJ. Apoptosis. Immunol Today. 14:1993;126-130.
2. Nagata S. Apoptosis by death factor. Cell. 88:1997;355-365.
3. Krammer PH, Dhein J, Walczak H, Behrmann I, Mariani S, Matiba B, Fath M, Daniel PT, Knipping E, Westendorp MO, Stricker K, Bäumler C, Hellbardt S, Germer M, Peter ME, Debatin K-M. The role of APO-1-mediated apoptosis in the immune system. Immunol Rev. 142:1994;175-191.
4. Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell. 75:1993;1169-1178.
5. Takahashi T, Tanaka M, Inazawa J, Abe T, Suda T, Nagata S. Human Fas ligand: gene structure, chromosomal location and species specificity. Int Immunol. 6:1994;1567-1574.
6. Kayagaki N, Kawasaki A, Ebata T, Ohmoto H, Ikeda S, Inoue S, Yoshino K, Okumura K, Yagita H. Metalloproteinase-mediated release of human Fas ligand. J Exp Med. 182:1995;1777-1783.
7. Tanaka M, Suda T, Takahashi T, Nagata S. Expression of the functional soluble form of human fas ligand in activated lymphocytes. EMBO J. 14:1995;1129-1135.
8. Griffith TS, Ferguson TA. The role of FasL-induced apoptosis in immune privilege. Immunol Today. 18:1997;240-244.
9. Berke G. The CTL's kiss of death. Cell. 81:1995;9-12.
10. Lowin B, Hahne M, Mattmann C, Tschopp J. Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways. Nature. 370:1994;650-652.
11. Kägi D, Vignaux F, Ledermann B, Burki K, Depraetere V, Nagata S, Hengartner H, Golstein P. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science. 265:1994;528-530.
12. Kabelitz D, Pohl T, Pechhold K. Activation-induced cell death (apoptosis) of mature peripheral T lymphocytes. Immunol Today. 14:1993;338-339.
13. Brunner T, Mogil RJ, LaFace D, Yoo NJ, Mahboubi A, Echeverri F, Martin SJ, Force WR, Lynch DH, Ware CF, Green DR. Cell autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature. 373:1995;441-444.
14. Dhein J, Walczak H, Baumler C, Debatin KM, Krammer PH. Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature. 373:1995;438-441.
15. Ju ST, Panka DJ, Cui H, Ettinger R, el Khatib M, Sherr DH, Stanger BZ, Marshak Rothstein A. Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature. 373:1995;444-448.
16. Alderson MR, Tough TW, Davis Smith T, Braddy S, Falk B, Schooley KA, Goodwin RG, Smith CA, Ramsdell F, Lynch DH. Fas ligand mediates activation-induced cell death in human T lymphocytes. J Exp Med. 181:1995;71-77.
17. Nagata S, Suda T. Fas and Fas ligand: lpr and gld mutations. Immunol Today. 16:1995;39-43.
18. Gutterman JU. Cytokine therapeutics: lessons from interferon alpha. Proc Natl Acad Sci U S A. 91:1994;1198-1205.
19. Tilg H. New insights into the mechanisms of interferon alfa: an immunoregulatory and anti-inflammatory cytokine. Gastroenterology. 112:1997;1017-1021.
20. Zhou A, Paranjape J, Brown TL, Nie H, Naik S, Dong B, Chang A, Trapp B, Fairchild R, Colmenares C, Silverman RH. Interferon action and apoptosis are defective in mice devoid of 2,5-oligoadenylate-dependent RNase L. EMBO J. 16:1997;6355-6363.
21. Tanaka M, Suda T, Haze K, Nakamura N, Sato K, Kimura F, Motoyoshi K, Mizuki M, Tagawa S, Ohga S, Hatake K, Drummond AH, Nagata S. Fas ligand in human serum. Nat Med. 2:1996;317-322.
22. Singer GG, Abbas AK. The Fas antigen is involved in peripheral but not thymic deletion of T lymphocytes in T cell receptor transgenic mice. Immunity. 1:1994;365-371.
23. Castro JE, Listman JA, Jacobson BA, Wang Y, Lopez PA, Ju S, Finn PW, Perkins DL. Fas modulation of apoptosis during negative selection of thymocytes. Immunity. 5:1996;617-627.
24. Hirsch RL, Johnson KP. The effects of long-term administration of recombinant alpha-2 interferon on lymphocyte subsets, proliferation, and suppressor cell function in multiple sclerosis. J Interferon Res. 6:1986;171-177.
25. Aulitzky WE, Tilg H, Vogel W, Aulitzky W, Berger M, Gastl G, Herold M, Huber C. Acute hematologic effects of interferon alpha, interferon gamma, tumor necrosis factor alpha and interleukin 2. Ann Hematol. 62:1991;25-31.
26. Pender MP. Genetically determined failure of activation-induced apoptosis of autoreactive T cells as a cause of multiple sclerosis. Lancet. 351:1998;978-981.
27. Selleri C, Sato T, Del Vecchio L, Luciano L, Barrett AJ, Rotoli B, Young NS, Maciejewski JP. Involvement of Fas-mediated apoptosis in the inhibitory effects of interferon-α in chronic myelogenous leukemia. Blood. 89:1997;957-964.
28. Castelli JC, Hassel BA, Wood KA, Li X-L, Amemiya K, Dalakas MC, Torrence PF, Youle RJ. A study of the interferon antiviral mechanism: apoptosis activation by the 2-5A system. J Exp Med. 186:1997;967-972.
29. Galle PR, Hofmann WJ, Walczak H, Schaller H, Otto G, Stremmel W, Krammer PH, Runkel L. Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. J Exp Med. 182:1995;1223-1230.
30. Hiramatsu N, Hayashi N, Katayama K, Mochizuki K, Kawanishi Y, Kasahara A, Fusamoto H, Kamada T. Immunohistochemical detection of Fas antigen in liver tissue of patients with chronic hepatitis C. Hepatology. 19:1994;1354-1359.
31. Kondo T, Suda T, Fukuyama H, Adachi M, Nagata S. Essential roles of the Fas ligand in the development of hepatitis. Nat Med. 3:1997;409-413.
32. Seino K-I, Kayagaki N, Takeda K, Fukao K, Okumura K, Yagita H. Contribution of Fas ligand to T cell-mediated hepatic injury in mice. Gastroenterology. 113:1997;1315-1322.
33. Fattovich G, Giustina G, Favarato S, Ruol A. A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol. 24:1996;38-47.
34. Giordano C, Stassi G, De Maria R, Todaro M, Richiusa P, Papoff G, Ruberti G, Bagnasco M, Testi R, Galluzzo A. Potential involvement of Fas and its ligand in the pathogenesis of Hashimoto's thyroiditis. Science. 275:1997;960-963.
35. Chervonsky AV, Wang Y, Wong FS, Visintin I, Flavell RA, Janeway CA Jr, Matis LA. The role of Fas in autoimmune diabetes. Cell. 89:1997;17-24.
36. Kaser A, Molnar C, Tilg H. Differential regulation of interleukin 4 and interleukin 13 production by interferon α Cytokine. 10:1998;75-81.
37. Cascino I, Fiucci G, Papoff G, Ruberti G. Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing. J Immunol. 154:1995;2706-2713.
38. Katsikis PD, Wunderlich ES, Smith CA, Herzenberg LA. Fas antigen stimulation induces marked apoptosis of T lymphocytes in human immunodeficiency virus-infected individuals. J Exp Med. 181:1995;2029-2036.
39. Lenardo MJ. Interleukin-2 programs mouse αβ T lymphocytes for apoptosis. Nature. 353:1991;858-861.
40. Martin SJ, Reutelingsperger CPM, McGahon A, Rader JA, van Schie RCAA, LaFace DM, Green DR. Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. J Exp Med. 182:1995;1545-1556.
41. Kiener PA, Davis PM, Starling GC, Mehlin C, Klebanoff SJ, Ledbetter JA, Liles WC. Differential induction of apoptosis by Fas-Fas ligand interactions in human monocytes and macrophages. J Exp Med. 185:1997;1511-1516.